Benefits of a fash dose of corticosteroids in digestive surgical oncology: A multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH)

The modulation of perioperative inflammation seems crucial to improve postoperative morbidity and cancer-related outcomes in patients undergoing oncological surgery. Data from the literature suggest that perioperative corticosteroids decrease inflammatory markers and might be associated with fewer complications in esophageal, liver, pancreatic and colorectal surgery.